Management of high peritoneal transporters

Peritoneal Dialysis International

Volumn 20, Issue SUPPL. 2, 2000, Pages

  Agrawal, Alok ^a   Nolph, Karl D ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

High transporters; Protein loss; Ultrafiltration failure

Indexed keywords

AMINO ACID; BICARBONATE; CHONDROITIN SULFATE; DERMATAN SULFATE; GLUCOSE; GLYCOSAMINOGLYCAN; HEPARIN; HYALURONIC ACID; ICODEXTRIN; LACTIC ACID; OSMOTIC AGENT;

ARTICLE; ATHEROSCLEROSIS; BED REST; BIOCOMPATIBILITY; BLOOD PRESSURE REGULATION; CLEARANCE; DIURETIC THERAPY; FLUID INTAKE; FLUID RETENTION; GLUCOSE ABSORPTION; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; MALNUTRITION; MEMBRANE TRANSPORT; METABOLIC DISORDER; MORTALITY; PATIENT CODING; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; SALT INTAKE; SURVIVAL; TECHNIQUE; ULTRAFILTRATION; URINE VOLUME;

EID: 0034130906     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002002s30     Document Type: Article

References (43)

1. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
2. Twardowski ZJ. Nightly peritoneal dialysis: Why, who, how, and when. ASAIO Trans 1990; 36(1):8-16.
3. Nolph KD, Mactier R, Khanna R, Twardowski ZJ, Moore H, McGary T. The kinetics of ultrafiltration during peritoneal dialysis: The role of lymphatics. Kidney Int 1987; 32:219-26.
4. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; [In press].
5. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D, for the CANUSA peritoneal dialysis study group. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998; 9:1285-92.
6. Blake PG, Abraham G, Somolosk K, Izzat S, Weissgarten J, Oreopoulos DG. Changes in peritoneal membrane transport rates in patients on long term CAPD. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1989; 5:3-7.
7. Nolph KD. A survey of ultrafiltration in continuous ambulatory peritoneal dialysis. An international cooperative study. Third report. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in CAPD. Toronto: Peritoneal Dialysis Bulletin, 1985; 1:79-86.
8. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
9. Moriishi M, Kawanishi H, Katsuni M, Harada Y, Sakikubo E, Matsumoto T, et al. Peritoneal resting in long term peritoneal dialysis patients [Abstract]. Perit Dial Int 2000; 20(Suppl 1):S11.
10. Van Biesen W, Waterloos M, Vogeleere P, Naggi A, Lameire N. Use of chondroitin sulfate as an additive to glucose-containing dialysate [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S11.
11. Gokal R, Mistry CD, Peers EM, and the Midas study group. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. Perit Dial Int 1995; 15:226-30.
12. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG. Serum albumin in patients on continuous ambulatory peritoneal dialysis. Predictors and correlations with outcomes. J Am Soc Nephrol 1993; 3(8):1501-7.
13. Burkart JM. Effect of peritoneal dialysis prescription and transport characteristics on nutritional status. Perit Dial Int 1995; 15(5, Suppl):S20-35.
14. Mamoun H, Anderstam B, Lindholm B, Södersten P, Bergström J. Peritoneal dialysis solutions with glucose and amino acids suppress appetite in rats [Abstract]. J Am Soc Nephrol 1994; 5:498.
15. Nolph KD, Moore HL, Prowant BF, Twardowski ZJ, Khanna R, Gamboa S, et al. Continuous ambulatory peritoneal dialysis with a high flux membrane. A preliminary report. ASAIO Trans 1993; 39:M556-68.
16. Kathuria P, Moore HL, Khanna R, Twardowski ZJ, Goel S, Nolph KD. Effect of dialysis modality and membrane transport characteristics on dialysate protein losses of patients on peritoneal dialysis. Perit Dial Int 1997; 17:449-54.
17. Donate T, Oliver A, Facundo C, Martinez J, Roda M, Barcelo P. Oral protein supplement efficacy in peritoneal dialysis (PD) patients (II) [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S15.
18. Kopple JD, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. 1995; 47:1148-57.
19. Kennedy M, Kerr L, Dasgupta M, Chang W, Perry D, Jumpsen J, et al. Randomized clinical trial of intraperitoneal amino acid (IPAA) solution in a North American peritoneal dialysis center. Preliminary data [Abstract]. Peru Dial Int 1999; 19(Suppl 1):S19.
20. Kamat N, Razzak N, Pat B, Turek D, Light PD. Effect of oral supplementation of 8 grams mixed amino acids on serum albumin in hypoalbuminemic CAPD patients [Abstract]. Perit Dial Int 2000; 20(Suppl 1):S24.
21. Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Increased peritoneal permeability is associated with decreased fluid and small solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 1998; 13(5):1242-9.
22. Heimbürger O, Stenvinkel P, Berglund L, Tranæus A, Lindholm B. Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996; 72:135-44.
23. Heimbürger O, Jogestrand T, Wang T, Lindholm B, Stenvinkel P. High peritoneal transport rate in patients starting PD is related to early signs of atherosclerosis [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S7.
24. Chu WS, Kim JK, Yi HA, Kim YH, Lee IS, Chung SH, et al. Peritoneal membrane hyperpermeability is an independent risk factor for CAPD mortality [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S51.
25. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport rate a risk factor for CAPD mortality? [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S52.
26. Wu CH, Huang CC, Huang JY, Wu MS, Leu ML. High flux peritoneal membrane is a risk factor in survival of CAPD treatment. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1996; 12:105-9.
27. Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13:962-8.
28. Fried L. Higher membrane permeability predicts poorer patient survival. Perit Dial Int 1997; 17:387-9.
29. Passadakis R, Thodis S, Panagoutos E, Selsiou E, Pita E, Vargemezis V. CAPD patients' outcome is not predicted by peritoneal permeability characteristics [Abstract]. Perit Dial Int 2000; 20(Suppl 1):S71.
30. Blake P, Burkart JM, Churchill DN, Daugirdas J, Depner T, Hamburger RJ, et al. Recommended clinical practices for maximizing peritoneal dialysis clearances. Perit Dial Int 1996; 16:448-56.
31. Hung KY, Lin TJ, Tsai TJ, Chen WY. Impact of peritoneal membrane transport on technique failure and patient survival in a population on automated peritoneal dialysis. ASAIO J 1999; 45(6):568-73.
32. Fried L, Bernardini B, Piraino B. APD does not improve outcomes in high transporters [Abstract]. Perit Dial Int 2000; 20 (Suppl 1):S64.
33. Heaf J. CAPD adequacy and dialysis morbidity: Detrimental effects of a high peritoneal equilibration rate. Ren Fail 1995; 17:575-87.
34. Mistry CD, Gokal R, Peers E, and the Midas Study Group. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46:496-503.
35. Howe A, Senior H, Brown EA. Use of icodextrin: Could it extend time on PD? [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S54.
36. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int 1997; 17:84-6.
37. Woodrow G, Stables G, Oldroyd B, Gibson J, Turney JH, Brownjohn AM. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant 1999; 14:1530-5.
38. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1999; 12:550-3.
39. Bajo MA, Selgas R, Hevia C, Castro MJ, Aguilera A, Millan I, et al. Icodextrin 7.5% dialysate for diurnal exchange in patients treated with CCPD [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S49.
40. Bajo MA, Selgas R, Castro MA, Castro MJ, Del Peso G, Aguilera A, et al. Effect of icodextrin on mesothelial cell growth in culture [Abstract]. Perit Dial Int 2000; 20(Suppl 1):S55.
41. Martis L, Topley N, Holmes CJ. Conventional and newer peritoneal dialysis solutions. In: Owen WF, Pereira JG, Sayegh MH, eds. Dialysis and transplantation: A companion to Brenner and Rector's The kidney. Philadelphia: W.B. Saunders Company; 2000: 179-98.
42. Emerson PF, Ruan J, McLaughlin BE, Keshaviah PR, DeLeo MA, Piscopo D. Effect of low-frequency ultrasound on peritoneal transport in rabbits. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1997; 13:77-80.
43. Chaimovitz C, Zlotnik M, Ben-David A, Zicherman Y. Extracorporeal abdominal vibration as a method for improving solute and fluid transport in peritoneal dialysis [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S14.